A Case of Ascending Colon Cancer Showing Marked Reduction of Ascites by Bevacizumab Combination Chemotherapy

A 68-year-old woman presented to our hospital with abdominal fullness. Computed tomography(CT)revealed ascites and massive tumors in the abdominal cavity. She was diagnosed with ascending colon cancer with peritoneal dissemination and ovarian metastasis. After ileostomy, panitumumab plus mFOLFOX6 th...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 42; no. 9; p. 1119
Main Authors Kusama, Toshiyuki, Higashida, Akihiro, Komatsubara, Takashi, Nishigori, Hideaki, Kokado, Yujiro, Ishii, Masayuki
Format Journal Article
LanguageJapanese
Published Japan 01.09.2015
Subjects
Aged
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Ascites - etiology
Bevacizumab
Colon, Ascending - pathology
Colonic Neoplasms - drug therapy
Colonic Neoplasms - pathology
Fatal Outcome
Female
Humans
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - secondary
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - secondary
Online AccessGet more information

Cover

More Information
Summary:A 68-year-old woman presented to our hospital with abdominal fullness. Computed tomography(CT)revealed ascites and massive tumors in the abdominal cavity. She was diagnosed with ascending colon cancer with peritoneal dissemination and ovarian metastasis. After ileostomy, panitumumab plus mFOLFOX6 therapy was initiated, but it was discontinued due to adverse events. As the ascites rapidly increased, her chemotherapy was changed to bevacizumab(BV)plus FOLFIRI. BV combination therapy resulted in a dramatic decrease in ascites and improved her quality of life, whereas the therapy did not reduce the primary and metastatic lesions. Our case suggested that BV could decrease ascites by inhibiting vascular endothelial growth factor(VEGF)-induced vascular permeability.
ISSN:0385-0684